Explore seven biotech companies advancing clinical drugs in the race for regulatory approval to revolutionize hepatitis B ...

Gain valuable insights into novel therapies, ongoing clinical trials, and future innovations shaping the treatment of ...

Viral hepatitis was the most common cause of infectious disease mortality worldwide after tuberculosis in 2024, according to ...

Premium InsightsThe Hepatitis C drug market is entering a transformative phase as global health organizations, pharmaceutical ...

US biotech Atossa Therapeutics (Nasdaq: ATOS) has entered into a research collaboration with China-backed Nona Biosciences, aiming to identify next-generation antibody therapies for breast cancer ...

The greatest distributors of hepatitis A virus are children. When they become infected with the virus, they do not get very sick — usually not sick enough to exhibit jaundice — but they ...

HONG KONG, March 30, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) ("Akeso", "the Company") released its 2024 annual report, emphasizing the company's key achievements in drug research, clinical ...

Chronic hepatitis B (CHB) is a long-term infection of the liver caused by the hepatitis B virus (HBV). While acute hepatitis B infection is often resolved by the immune system, CHB occurs when the ...

But promising results from a recent clinical trial suggest that broadly neutralizing antibody therapy (bNAbs) may be able to accomplish the next best thing. Data from the trial—a collaboration ...